↓ Skip to main content

Dove Medical Press

Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients

Overview of attention for article published in OncoTargets and therapy, October 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
103 Dimensions

Readers on

mendeley
54 Mendeley
Title
Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients
Published in
OncoTargets and therapy, October 2013
DOI 10.2147/ott.s52805
Pubmed ID
Authors

Ling He, Kuan Peng, Yizhi Liu, Jing Xiong, Fu-fan Zhu

Abstract

Mixed lineage kinase domain-like protein (MLKL) was initially identified as a key receptor interacting protein 3 downstream component of tumor-necrosis-factor-induced necrosis. In this study, we characterized the expression of MLKL in ovarian carcinomas and evaluated the prognostic value of MLKL in patients with ovarian cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Unknown 53 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 13%
Researcher 7 13%
Student > Ph. D. Student 7 13%
Student > Doctoral Student 6 11%
Student > Bachelor 4 7%
Other 7 13%
Unknown 16 30%
Readers by discipline Count As %
Agricultural and Biological Sciences 9 17%
Medicine and Dentistry 8 15%
Biochemistry, Genetics and Molecular Biology 8 15%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Chemistry 3 6%
Other 3 6%
Unknown 20 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2013.
All research outputs
#4,835,465
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#218
of 3,016 outputs
Outputs of similar age
#41,630
of 219,840 outputs
Outputs of similar age from OncoTargets and therapy
#3
of 34 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.